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Abstract Though the cell surface-associated costimulator B7-
1(CD80) is known to be highly N-glycosylated, the functional
significance of this N-glycosylation has not been evaluated. Two
experimental approaches were taken to assess the influence of N-
glycosylation on human B7-1 function. First, stable K562
transfectants expressing human B7-1 were treated with the N-
glycosylation inhibitor tunicamycin. This treatment reduced the
levels of B7-1 at the cell surface as judged by both indirect
immunofluorescence/flow cytometry and immunoprecipitation
analyses. Significantly, the non-glycosylated cell surface-asso-
ciated B7-1 on tunicamycin-treated cells retained the capacity to
bind CTLA-4WIg, a soluble derivative of the CTLA-4(CD152)
counter-receptor. Second, experiments were performed with
bacterially-produced non-glycosylated derivatives of human B7-
1, comprising either the complete B7-1 extracellular domain
(hB7-1Wed) or the membrane-proximal IgC-homologue domain of
B7-1 in isolation (hB7-1WIgC). While the hB7-1WIgC derivative
failed to bind to CTLA-4, the larger hB7-1Wed derivative
associated with CTLA-4WIg in cell-free binding assays. Futher-
more, recombinant hB7-1Wed effectively blocked B7-1-mediated
costimulation in an in vitro T cell proliferation assay, suggesting
that this soluble non-glycosylated B7-1 derivative is capable of
engaging CD28, the B7 counter-receptor implicated in T cell
activation. Taken together, these data indicate that the N-
glycosylation of B7-1 is not required for its association with
counter-receptors. Moreover, the findings pave the way for the
therapeutic use of recombinant bacterial B7-1 derivatives as
competitive inhibitors of B7-mediated signals.
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1. Introduction
T cell activation requires signaling through both antigen
and costimulator receptors [1^3]. Although costimulator func-
tion has been ascribed to a variety of cell surface proteins
[1,4], two of them, B7-1(CD80) and B7-2(CD86), are thought
to be especially important [5^8]. Each of these B7 proteins can
associate with two structurally-distinct counter-receptors on T
cells, CD28 and CTLA-4(CD152), with the former serving as
the primary activating receptor [8].
T cell receptor engagement in the absence of costimulation
can result in the induction of T cell non-responsiveness [9,10].
This experimental observation has led to attempts to invoke
costimulator blockade as a therapeutic means for attenuating
pathogenic T cell function [11,12]. A soluble derivative of the
CTLA-4 receptor, CTLA-4WIg, has been studied widely and
has shown some therapeutic promise as a competitive inhib-
itor of B7-driven costimulatory signaling [11^16], although in
some animal disease models this agent has proven less e¡ec-
tive [17^19]. While this limited e⁄cacy may point to parallel
signaling by other costimulators, it may also result from prob-
lems inherent to CTLA-4WIg itself. Alternative agents for
blocking the B7/CD28 axis have also been considered. The
infusion of anti-B7-1 and anti-B7-2 mAbs in combination
was e¡ective in eliminating GVHD lethality in one animal
model [20], but studies in other in vivo systems have not
shown similar e⁄cacy for anti-B7 mAbs [16,21,22], possibly
as a consequence of host responses to the infused antibodies
[23]. In principle, recombinant soluble B7 protein derivatives
might also be used as competitive inhibitors of the B7/CD28
signaling axis. However, B7WIg fusion proteins (produced in
mammalian expression systems) [24^26] and B7 extracellular
domain derivative proteins (produced in yeast expression sys-
tems) [27] have not been invoked for the purpose of compet-
itive blockade of T cell activation. To date, there have been no
reports on bacterially-produced B7 proteins, and hence there
is no indication as to whether non-glycosylated recombinant
B7 proteins of this sort might retain counter-receptor a⁄nity,
and hence competitive inhibitory potential.
Human B7-1 and B7-2 are type I membrane proteins, each
with an extracellular domain consisting of one IgV-homo-
logue domain unit linked in tandem to one IgC-homologue
domain unit. A prominent structural feature of the B7 pro-
teins is their N-glycosylation [6], with human B7-1 sequence
displaying eight potential acceptor sites for N-linked glycosyl-
ation [5]. However, the extent of usage of each site has not
been established, and the role of glycosylation in B7 activities
has not been systematically investigated.
In the present study, the contribution of N-glycosylation to
the ability of human B7-1 to associate with its counter-recep-
tors is evaluated. The complementary experimental ap-
proaches in this study invoke non-glycosylated B7-1 on tuni-
camycin-treated mammalian cell transfectants on the one
hand, and recombinant soluble B7-1 proteins produced in
bacterial cell transformants on the other. The possibility of
using bacterial B7 protein derivatives, reported here for the
¢rst time, as therapeutic agents emerges.
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2. Materials and methods
2.1. Mammalian cell transfectants
Full-length coding sequence for human B7-1 was mobilized from
the plasmid phB7-1/cEXV-3 (provided by J. Miller, University of
Chicago) [28] by digesting with EcoRI, and the insert was ligated
into the corresponding site of pBT (Bluescript; Stratagene, Inc., La
Jolla, CA), generating phB7-1/BT. The full-length cDNA was then
excised from phB7-1/BT with BamHI and HindIII and was subcloned
into the corresponding sites of our Epstein-Barr virus episomal ex-
pression vector pREP10 (distributed by Invitrogen Co., San Diego,
CA), generating the expression construct phB7-1/REP10.
phB7-1/REP10 was introduced into K562 myeloid leukemic cells
(American Type Culture Collection, Rockville, MD) by lipofection
as described [29]. Brie£y, K562 cells were lipofected in serum-free
medium using 30 Wl of lipofectin reagent (Life Technologies, Grand
Island, NY) and 10 Wg of plasmid DNA. Cells were selected in the
presence of 200 Wg/ml of hygromycin B (Calbiochem-Novabiochem
Co., La Jolla, CA). Drug-resistant cells were pooled and used un-
cloned.
2.2. Production of recombinant bacterial proteins
Oligonucleotides used for generating B7 expression constructs by
PCR were as follows: primer A: 5P-AGCGAATTCGGTCTTTCTC-
ACTTCTGTTCAGGT-3P ; primer B: 5P-TATGCGGGATCCTTAG-
TGGTGGTGGTGGTGGTGAAGCTTGT TATCAGGAAAATGC-
TCTTG-3P ; primer C: 5P-TAGCGAATTCAAAGCTGACTTCCCT-
ACACCT-3P ; primer D: 5P-ACTGGCTAAAGCTTTTATTGCTTG-
GTTGTATTCCAGTTG-3P ; primer E: 5P-TAGCGAATTCGGTCT-
TTCTCACTTCTGTTCAGGT-3P ; primer F: 5P-ATTAGAATAAG-
CTTTTAGACTGATAACGTCACTTCAGCCAG-3P.
A bacterial expression construct for human B7-1 was produced in a
step-wise fashion, with a Pichia expression construct as an intermedi-
ate. To start, a cDNA sequence encompassing the complete extracel-
lular domain of human B7-1 (Gly1^Asn216) was generated by PCR
using phB7-1/BT as template, and primers A and B as 5P- and 3P-end
primers, respectively. The PCR product was co-digested with EcoRI
and BamHI and ligated into the corresponding sites of the Pichia
expression vector pHIL-S1 (Invitrogen Co., San Diego, CA), generat-
ing phB7-1/HIL-S1. The construct was veri¢ed by DNA sequencing at
this stage. In turn, the hB7-1 coding sequence was mobilized from
phB7-1/HIL-S1 by EcoRI and HindIII co-digestion, and the recovered
insert was ligated into the corresponding sites of the bacterial expres-
sion vector pHH/ET22b, generating phB7-1WedWHH/ET22b. The vector
pHH/ET22b had previously been derived by us [30] from pET-22b(+)
(Novagen).
A cDNA sequence encompassing only the membrane-proximal IgC
domain (Lys113^Gln210) of human B7-1 was generated by PCR using
phB7-1/BT as template, and primers C and D as 5P- and 3P-end prim-
ers, respectively. The PCR product was co-digested with EcoRI and
HindIII and ligated into the corresponding sites of pHH/ET22b, gen-
erating phB7-1WIgCWHH/ET22b. In similar fashion, a cDNA sequence
encompassing only the IgV domain (Gly1^Val112) of human B7-1 was
generated by PCR, in this case using phB7-1/BT as template, and
primers E and F as 5P- and 3P-end primers, respectively. The PCR
product was co-digested with EcoRI and HindIII and ligated into the
corresponding sites of pHH/ET22b, generating hB7-1WIgVWHH/ET22b.
The coding sequences within both PCR-derived expression constructs
were veri¢ed by DNA sequencing.
The bacterial expression constructs were separately transformed
into E. coli BL21(DE3). Ampicillin-resistant single colonies were
picked and assessed for B7 protein expression after induction by
1 mM IPTG. Quantitative amounts of the proteins were prepared
in one-liter batches. hB7-1WIgC was puri¢ed from the periplasm of
bacterial transformants according to the manufacturer’s protocol (No-
vagen). Brie£y, bacteria were pelleted, washed with PBS, resuspended
in 0.4 culture volumes of 30 mM Tris-HCl pH 8.0/20% sucrose.
EDTA was added to 1 mM and the suspension was incubated for
5 min at room temperature (RT) with shaking. Bacteria were collected
and resuspended in 0.4 culture volumes of ice-cold 5 mM MgSO4. The
suspension was incubated for 10 min on ice with shaking. After cen-
trifugation, the supernatant represents the periplasmic fraction. hB7-
1WIgC was puri¢ed from the periplasmic fraction by Ni2-Sepharose
chromatography.
hB7-1Wed and hB7-1WIgV were puri¢ed according to a published
protocol [31] with modi¢cations. Brie£y, bacterial cells were collected
by centrifugation and lysed by treating with lysozyme (1 mg/ml) and
sonicating at 4‡C. The resulting lysate was centrifuged at 1100Ug for
8 min to remove unbroken cells. Inclusion bodies were subsequently
collected from the lysate by centrifuging at 25 000Ug for 30 min.
Partially puri¢ed inclusion bodies (PPIB) were dissolved in 2% sodium
lauroylsarcosine (Sigma)/50 mM Tris-HCl, pH 10.0 (500 ml detergent
solution per 1 l of starting bacterial culture). Renaturation was per-
formed in the presence of 50 WM copper sulfate at RT for 20 h. After
this step, 2 ml of charged HisWBind Sepharose (Novagen) was added
(per 500 ml), and batch absorption was conducted over a 16-h period.
Protein-bound beads were collected and packed into a column. The
column was washed and proteins were eluted with an imidazole bu¡er
according to the manufacturer’s protocol (Novagen). The fractions
were analyzed by SDS-PAGE, and the protein-containing fractions
were combined and dialyzed vs. PBS. Non-covalent aggregates that
formed during the dialysis procedure were removed by centrifugation.
2.3. Indirect immuno£uorescence/£ow cytometry
K562 cells and transfectants were washed twice in wash bu¡er
(0.25% BSA/0.1% (w/v) sodium azide/PBS). 106 washed cells were
incubated on ice for 1 h with 100 Wl of the wash bu¡er containing
1 Wg of hB7-1-speci¢c mAb BB-1 (Becton-Dickinson) or with 100 Wl
of spent culture medium containing CTLA-4WIg prepared as described
[32]. The cells were washed twice and incubated on ice for 1 h with
50 Wl 1:100 diluted FITC-conjugated goat F(abP)2 anti-mouse Ig (for
BB-1), or anti-human Ig (for CTLA-4WIg) (Boehringer Mannheim Bi-
ochemicals). The cells were washed twice, ¢xed in 500 Wl of 2% para-
formaldehyde/wash bu¡er, and analyzed on a FACStar (Becton-
Dickinson).
2.4. Surface biotinylation and immunoprecipitation
K562 cells were washed three times in ice-cold PBS, pH 8.0 and
resuspended at 107 cells/ml in 1 mg/ml of sulfo-NHS-biotin (Pierce,
Rockford, IL) dissolved in PBS, pH 8.0. The cells were incubated at
4‡C for 30 min with gentle mixing. The labeling reactions were
quenched by adding serum-free RPMI-1640. The excess biotin was
removed by washing cells four times with PBS. The surface-biotinyl-
ated cells (5U107) were lysed in 1 ml of 1% Nonidet P40/150 mM
NaCl/50 mM Tris-HCl, pH 8.0/1 mM PMSF at 4‡C for 1 h. The
lysate was spun in a microfuge for 30 min to remove debris, pre-
cleared with protein G-agarose (Gibco-BRL), and immunoprecipi-
tated with 60 Wl of protein G-agarose slurry (50%) and 1 Wg of BB-
1 or 2 Wg of CTLA-4WIg at 4‡C for 16 h. Beads were washed, spun
over a sucrose gradient, and washed again as described [30]. The
immunoprecipitates were fractionated on a 10% SDS-polyacrylamide
gel and electro-transferred to nitrocellulose membrane. The membrane
was blocked in 3% BSA/PBS, washed with 0.5% BSA/T-PBS (0.1%
Tween-20 in PBS), and incubated with streptavidin-horseradish per-
oxidase conjugate (Amersham Co., Arlington Heights, IL) diluted in
1% BSA/T-PBS. The membrane was washed in T-PBS, developed
with enhanced chemiluminescence reagent (ICN Biomedicals, Inc.,
Irvine, CA), and exposed to X-ray ¢lm.
2.5. Solid-phase binding assays
In one type of binding assay, test or control protein was bound to
Immulon-4 wells (Dynatech, Chantilly, VA) at 10 Wg/ml in 100 Wl of
PBS for 4 h at 37‡C. Wells were washed with wash bu¡er (0.5% BSA/
0.05% Tween-20/PBS) and blocked with 200 Wl blocking bu¡er (3%
BSA/0.05% Tween-20/PBS) for 16 h at 4‡C. Wells were washed and
incubated for 2 h at 37‡C with 100 Wl of 10 Wg/ml CTLA-4WIg diluted
in the wash bu¡er. Plates were washed and then incubated for 2 h at
37‡C with 100 Wl of 1:800 diluted HRP-conjugated anti-human IgG1
Ab (The Binding Site Ltd, Birmingham, UK). Plates were washed,
developed, and analyzed as described [30]. All experiments were per-
formed in triplicate.
Alternatively, 1 Wg of CTLA-4WIg was bound to Immulon-4 for 4 h
at 37‡C. Wells were washed, blocked, and incubated for 4 h at 37‡C
with 100 Wl of 10 Wg/ml bacterial protein diluted in PBS. Plates were
washed and incubated for 2 h at 37‡C with the anti-hemagglutinin
(HA) antibody 12CA5 (provided by D. Templeton, CWRU) at a ¢nal
concentration of 0.25 Wg/ml in the wash bu¡er. Wells were washed
and incubated for 2 h at 37‡C with 100 Wl 1:2000 diluted HRP-con-
jugated goat anti-mouse Ig (BioRad). Plates were washed, developed,
and analyzed. All experiments were performed in triplicate.
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2.6. CTLA-4WIg-agarose bead binding assay
CTLA-4WIg was cross-linked to protein G-agarose beads as de-
scribed [33]. hB7-1Wed at 100 Wg/ml in PBS was mixed with CTLA-
4WIg-conjugated beads for 16 h with gentle mixing at 4‡C. The beads
were collected, packed into a column, and washed with PBS. hB7-1Wed
was eluted from the beads with 100 mM glycine, pH 2.5 in 0.5-ml
fractions and immediately neutralized with 200 mM Na2HPO4.
2.7. Costimulation assays
Peripheral blood mononuclear cells (PBMC) were isolated from
fresh whole blood by Ficoll density centrifugation and depleted of
adherent cells by incubation in plastic £asks for 1 h at 37‡C. T cells
were puri¢ed by two rounds of treatment with Lympho-kwik (One
Lambda, Inc., Canoga Park, CA). T cell purity was veri¢ed by the
lack of a T cell proliferative response to PHA or PMA in the absence
of accessory cells. To analyze proliferation, 1U105 T cells were incu-
bated in £at-bottom 96-well plates with 1 ng/ml PMA and mitomycin
C treated hB7-1-expressing K562 transfectant cells (8U104 in Fig. 6,
panel A and 2U104 in Fig. 6, panel B) for 60 h. Wells were pulsed
with 1 WCi 3H-thymidine for the last 16 h of the incubation period.
Cells were harvested and counted on a Betaplate liquid scintillation
counter.
In some inhibition experiments, CTLA-4WIg or control mCD8WIg
was included in the assays at a ¢nal concentration of 10 Wg/ml. In
other inhibition experiments, the immunoa⁄nity-puri¢ed bacterial
hB7-1Wed (or control bacterial protein) was included in the assays at
a ¢nal concentration of 1, 3, 9, or 27 Wg/ml.
3. Results
3.1. Non-glycosylated B7-1 on the surface of
tunicamycin-treated K562 transfectant cells binds to
CTLA-4WIg
In a ¢rst set of studies, the B7-1 N-glycosylation issue was
addressed in human cell transfectants. To this end, the human
myeloid leukemia cell line K562 was stably transfected with
the episomal expression construct phB7-1/REP10. Surface ex-
pression of human B7-1 on the transfectants was documented
by immunoprecipitation of cell surface-biotinylated cell ly-
sates. While parental K562 cells lacked detectable B7-1 (Fig.
1, lanes 1 and 3), transfected K562 cells expressed cell surface
B7-1 that could be readily immunoprecipitated with either the
anti-B7-1 mAb BB-1 (Fig. 1, lane 2) or CTLA-4WIg (Fig. 1,
lane 4). The observed molecular weight of V66 kDa agrees
with the predicted size of glycosylated human B7-1 [5]. The
e¡ect of tunicamycin, an inhibitor of N-linked glycosylation,
on B7-1 expression in the K562 transfectants was next eval-
uated. Transfectants treated with tunicamycin at 10 Wg/ml for
40 h displayed signi¢cantly decreased levels of B7-1 at their
cell surfaces as compared to the same transfectants treated
instead with the solvent DMSO only (Fig. 2, panels A and
B). The reduction in surface B7-1 (as evaluated by immuno-
£uorescence and £ow cytometry) was evident regardless of
whether an anti-B7-1 mAb (Fig. 2, panel A) or CTLA-4WIg
(Fig. 2, panel B) was used as the detecting reagent.
To more fully characterize the B7-1 protein on the surfaces
of tunicamycin-treated K562 transfectants, the protein was
immunoprecipitated from surface-biotinylated cell lysates.
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Fig. 2. CTLA-4WIg binds to non-glycosylated B7-1 of tunicamycin-treated mammalian cell transfectants. Panels A and B: phB7-1/REP10-trans-
fected K562 cells were cultured in the presence of tunicamycin (10 Wg/ml in DMSO solvent) (solid line) or the DMSO solvent only (dashed
line) for 40 h. The treated cells (solid and dashed lines) or control cells (dotted line) were immunostained with BB-1 mAb (panel A) or CTLA-
4WIg (panel B). FITC-conjugated goat anti-mouse Ig (BB-1) or goat anti-human Ig (CTLA-4WIg) were used as secondary Abs. Cells were ana-
lyzed on a FACScan £ow cytometer and plotted as arbitrary units of log10 £uorescence intensity vs. cell number. Panel C: The same phB7-1/
REP10-transfected K562 cells were cultured in the presence of tunicamycin (DMSO solvent) (lanes 3 and 4) or the DMSO solvent only (lanes
1 and 2) for 40 h. In each case, 5U107 cells were surface-biotinylated, and cell lysates were immunoprecipitated using BB-1 mAb (lanes 1 and
3) or CTLA-4WIg (lanes 2 and 4). Immunoprecipitates were fractionated by 10% SDS-PAGE and blotted onto nitrocellulose. Biotinylated pro-
teins were detected by streptavidin-HRP followed by ECL and £uorography.
Fig. 1. Surface expression of hB7-1 on K562 transfectant cells.
Non-transfected (lanes 1 and 3) or phB7-1/REP10-transfected (lanes
2 and 4) K562 cells were cell surface-biotinylated, and cell lysates
were immunoprecipitated using the human B7-1-speci¢c mAb BB-1
(lanes 1 and 2) or CTLA-4WIg (lanes 3 and 4). Immunoprecipitates
were fractionated by SDS-PAGE and developed as described in Sec-
tion 2.
A. Chen et al./FEBS Letters 428 (1998) 127^134 129
Two distinct populations of B7-1 molecules were evident. A
subset of the B7-1 protein from the tunicamycin-treated cells
co-migrated (at V66 kDa) with the B7-1 protein of control
DMSO-treated cells (Fig. 2, panel C), indicating that it had
retained its N-glycosylation despite tunicamycin treatment.
However, a second 30-kDa species was also clearly evident
in the tunicamycin-treated, but not the control DMSO-
treated, samples. The size of this protein species corresponds
to that predicted (based upon amino acid composition) for
non-glycosylated human B7-1 protein. Signi¢cantly, this
non-glycosylated B7-1 species was immunoprecipitated not
just by mAb BB-1 (Fig. 2, panel C, lane 3) but also by the
soluble B7 counter-receptor CTLA-4WIg (Fig. 2, panel C, lane
4). This ¢nding suggests that N-glycosylation is not necessary
for human B7-1 to bind to its counter-receptor CTLA-4.
It is noteworthy that consistent with the previous £ow cy-
tometric ¢nding, the immunoprecipitated samples showed sig-
ni¢cantly lower B7-1 levels on tunicamycin-treated cell sur-
faces (Fig. 2, panels A and B). When immunoprecipitation
was performed using biotinylated total cell lysates instead of
surface biotinylated ones, B7-1 levels were not a¡ected by
tunicamycin treatment (data not shown). These ¢ndings indi-
cate that tunicamycin does not inhibit B7-1 protein synthesis
per se and suggest that tunicamycin treatment may inhibit the
export and/or diminish the cell surface stability of B7-1 on
transfected cell surfaces. Of note, the B7-1 decrease is evident
for both the glycosylated and non-glycosylated species. In
addition, the recovery of non-glycosylated B7-1 from surface
biotinylated samples suggests that glycosylation is not an ab-
solute prerequisite for B7-1 exit to the cell surface.
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Fig. 4. Plate-based solid phase binding assay demonstrating speci¢c
interaction between recombinant hB7-1Wed and CTLA-4WIg proteins.
Panel A: hB7-1Wed protein (10 Wg/ml), puri¢ed by metal chelate af-
¢nity chromatography, was pre-coated onto wells of Immulon-4
plates, and CTLA-4WIg (10 Wg/ml) was added to the wells. After the
washing step, immobilized CTLA-4WIg was detected using HRP-con-
jugated anti-human IgG1 Ab. Panel B: The binding partners were
reversed (as compared to panel A) so that CTLA-4WIg (20 Wg/ml)
was pre-coated onto the wells, and hB7-1Wed (10 Wg/ml) binding was
monitored. Bound hB7-1Wed was detected using the anti-hemaggluti-
nin mAb 12CA5 as primary Ab and HRP-conjugated goat anti-
mouse Ig antiserum as secondary Ab. Bars indicate the mean ab-
sorbance and standard error of triplicate samples. The results are
representative of at least two independent experiments with similar
results.
Fig. 3. Puri¢cation of bacterially-expressed soluble human B7-1 pro-
tein derivatives. Panel A: Recombinant human B7-1Wed (full extra-
cellular domain) protein was puri¢ed from extracts of bacteria
transformed with phB7-1WedWHH/ET22b. Protein enrichment during
the refolding/puri¢cation process was monitored at each stage by
10% SDS-PAGE. Lane 1, molecular mass markers; lanes 2 and 3,
total lysates of uninduced and induced cells, respectively; lane 4,
partially puri¢ed inclusion bodies; lanes 5 and 6, pooled 1 M imida-
zole eluates from the Ni2-metal a⁄nity column. Samples were run
under reducing conditions except for lane 6. Panel B: Recombinant
human B7-1WIgC (IgC-homologue domain only) protein was puri¢ed
from extracts of bacteria transformed with phB7-1WIgCWHH/ET22b.
Protein enrichment during the refolding/puri¢cation process was
monitored at each stage by 15% SDS-PAGE. Lane 1, molecular
mass markers; lanes 2 and 3, total lysates of uninduced and induced
cells, respectively; lanes 4 and 5, periplasmic preparations before
and after incubation with HisWBind-Sepharose, respectively; lanes 6^
8, £ow-through during washing stage; lanes 9^11, fractions 1^3 dur-
ing imidazole elution of bound protein. Samples were run under re-
ducing conditions.
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3.2. Production of human B7-1 derivatives in a bacterial
expression system
To address the N-glycosylation question in a more direct
way, we shifted from the mammalian expression system to a
bacterial expression system which produces non-glycosylated
recombinant proteins. Bacterial expression of B7 proteins has
not been reported previously. To this end, we generated the
expression construct phB7-1WedWHH/ET22b which contains the
coding sequence for the full extracellular domain of human
B7-1 (designated hB7-1Wed), along with hexahistidine and
hemagglutinin epitope tags. Speci¢c accumulation of an
V32-kDa band was observed after IPTG induction (Fig. 3,
panel A, lanes 2 and 3). While the induced cells expressed high
levels of recombinant protein, periplasmic soluble protein
yields were poor because the protein formed inclusion body
aggregates (Fig. 3, panel A, lane 4). The inclusion bodies were
dissolved, refolded, and puri¢ed as described in Section 2.
After puri¢cation by nickel-chelate a⁄nity chromatography,
hB7-1Wed appeared as a dominant band under both reducing
(Fig. 3, panel A, lane 5) and non-reducing (Fig. 3, panel A,
lane 6) conditions, indicating that the protein is a monomer
under SDS-PAGE conditions. The refolded hB7-1Wed protein,
but not control protein thioredoxin, bound to the B7-1-spe-
ci¢c mAb BB-1 in a concentration-dependent manner (data
not shown). Overall, the puri¢cation/refolding e⁄ciency for
hB7-1Wed was 30%, with approximately 2 mg puri¢ed protein
obtained per liter of bacterial culture.
In addition to hB7-1Wed, two truncated derivatives of the
human B7-1 extracellular domain were produced in the
same bacterial expression system for inclusion in the subse-
quent counter-receptor binding analyses. These derivatives
consisted of the membrane-proximal IgC and amino-terminal
IgV domains of hB7-1, each on its own as isolated domain
units, and were produced in E. coli transformed with the ex-
pression constructs phB7-1WIgCWHH/ET22b and phB7-
1WIgVWHH/ET22b, respectively (see Section 2). In the case of
phB7-1WIgCWHH/ET22b transformants, signi¢cant accumula-
tion of an V20-kDa band was observed after IPTG induction
(Fig. 3, panel B, lane 3). Moreover, there was substantial
secretion of this hB7-1WIgC protein in soluble form into the
bacterial periplasm, contrasting with hB7-1Wed which accumu-
lated in insoluble inclusion bodies and did not e⁄ciently exit
into the periplasm. The periplasmic hB7-1WIgC protein could
be highly puri¢ed by single-step metal chelate chromatograpy
(Fig. 3, panel B, lanes 9^11). Though no Ab with speci¢city
for this isolated domain is available, the e⁄cient secretion
of hB7-1WIgC into the bacterial periplasm suggests that this
protein folds properly within the bacterial environment, and
as shown, migrates as expected at V20 kDa. Generally, ap-
proximately 5 mg of periplasmic hB7-1WIgC could be puri¢ed
from one liter of bacterial culture. In contrast, repeated
attempts to express the human hB7-1WIgV protein were un-
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Fig. 6. Soluble bacterially-produced human hB7-1Wed competitively
inhibits B7-1-dependent costimulation. Panel A: 105 puri¢ed human
T cells were combined with PMA (1 ng/ml) and 8U104 mitomycin
C-treated phB7-1/REP10-transfected K562 cells. E¡ective depletion
of accessory cells was documented in all T cell preparations by dem-
onstrating the lack of a response to PMA or PHA in the absence of
a source for costimulation. For inhibition of the costimulation,
CTLA-4WIg or control Ig was added to the cultures at a ¢nal con-
centration of 10 Wg/ml. All cultures were incubated for 60 h and
pulsed with 1 WCi of [3H]thymidine per well for the last 16 h of the
incubation period prior to determining [3H]thymidine incorporation.
Points are the means and standard errors of triplicate samples. The
data are representative of at least three independent experiments
with similar results. Panel B: 105 puri¢ed human T cells were com-
bined with PMA (1 ng/ml) and 2U104 mitomycin C-treated phB7-1/
REP10-transfected K562 cells. hB7-1Wed or control proteins at ¢nal
concentrations of 1, 3, 9, or 27 Wg/ml were included in the costimu-
lation assays (as characterized in panel A). Points are the means
and standard errors of triplicate samples. The data are representa-
tive of at least two independent experiments with similar results.
Fig. 5. Binding of hB7-1Wed to CTLA-4WIg-conjugated protein G-
agarose beads. hB7-1Wed protein (200 Wg/ml) was co-incubated for
16 h with CTLA-4WIg-conjugated protein G-agarose beads. The
beads were packed into a column and extensively washed with PBS,
and bound hB7-1Wed was eluted in 0.5-ml fractions with 100 mM
glycine, pH 2.5 and neutralized with 200 mM Na2HPO4. Fractions
were analyzed on a 10% SDS-PAGE. Lane 1, molecular mass
markers; lane 2, protein sample before the addition of the beads;
lane 3, the same amount of protein as in lane 2 after incubation
with the beads; lane 4, £ow-through during the washing stage; lanes
5^10, fractions 1^6 during 100 mM glycine (pH 2.5) elution.
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successful, with the protein aggregating in inclusion bodies
and failing to reconstitute the BB-1 mAb-interactive
epitope hat resides within this domain after the refolding pro-
cedure.
3.3. Non-glycosylated bacterially-produced human B7-1 binds
to CTLA-4
Two types of solid-phase binding assays were employed for
assessing the binding of soluble non-glycosylated B7-1 deriv-
atives to CTLA-4. First, CTLA-4WIg binding to immobilized
B7-1 vs. control proteins was evaluated, using HRP-conju-
gated anti-human IgG1 as a detecting reagent. Control pro-
teins for these experiments included recombinant isolated
IgSF domain proteins (domain 3 of mouse NCAM and the
K3 domain of HLA-A2.1) produced with the same bacterial
expression vectors, as well as BSA and bacterial thioredoxin
(TX) produced with the pET-32a(+) vector. As shown in Fig.
4 (panel A), CTLA-4WIg bound to hB7-1Wed, but not to hB7-
1WIgC or any of the negative control proteins (data from a
separate experiment with the HLA-A2.1 K3 domain and
BSA negative control proteins not shown).
Second, a sandwich ELISA format was used in which im-
mobilized CTLA-4WIg served to capture B7 derivatives which
were then detected with an mAb directed against the HA
epitope tag and HRP-conjugated goat anti-mouse Ig. Con-
sistent with the ¢ndings in the other ELISA, non-glycosylated
hB7-1Wed bound to CTLA-4WIg, whereas no signi¢cant binding
was observed for the truncated hB7-1WIgC or the control pro-
teins (Fig. 4, panel B).
An alternative assay was also employed that bypassed Im-
mulon-4 wells altogether. In this case, CTLA-4WIg was ¢rst
cross-linked to protein G-agarose, and the CTLA-4-conju-
gated beads were then shown to e⁄ciently adsorb the hB7-
1Wed protein (Fig. 5, lanes 2 and 3). Extensive washing did not
visibly release bound protein from the a⁄nity matrix (Fig. 5,
lane 4). The hB7-1Wed protein was readily eluted from the
beads with 100 mM glycine, pH 2.5 (Fig. 5, lanes 7^10). Tak-
en together, these results establish that glycosylation is not
required for B7-1/CTLA-4 interaction.
3.4. Non-glycosylated bacterial hB7-1Wed is functional as a
competitive inhibitor of cell surface B7-1-mediated
costimulation
We next determined whether the non-glycosylated B7-1
proteins expressed in E. coli can bind to the primary activat-
ing counter-receptor on T-cells, CD28. To this end, we de-
vised an assay paralleling one previously reported in which the
capacity of mutant B7WIg derivatives to block immobilized
B7WIg-mediated costimulation of T cell proliferation was as-
sessed as an indicator of CD28 engagement [26]. In our case,
human T cells were stimulated to proliferate with a subopti-
mal dose of the phorbol ester PMA and hB7-1-expressing
K562 transfectants in combination, providing the primary
and costimulatory signals, respectively. As expected, no pro-
liferation was observed in the presence of untransfected or
vector only-transfected K562 cells (data not shown), nor in
the absence of stimulator cells altogether (Fig. 6, panel A).
However, addition of hB7-1 K562 transfectant cells yielded
signi¢cant T-cell proliferation (Fig. 6, panel A), and the B7-
dependence of this costimulatory e¡ect was substantiated by
its complete inhibitability by CTLA-4WIg and not a control Ig
fusion protein. With the costimulation assay in place, we
asked whether soluble non-glycosylated (monomeric) B7-1 de-
rivatives could competitively block costimulation by B7-1 on
the surface of K562 transfectants. Signi¢cantly, hB7-1Wed
blocked T cell proliferation in a dose-dependent manner,
with near total inhibition achieved at V25 Wg/ml of hB7-
1Wed (Fig. 6, panel B). Similar levels of costimulatory blockade
were achieved with 10 Wg/ml CTLA-4WIg. In contrast, hB7-
1WIgC and control proteins displayed no inhibitory e¡ects.
Taken together, the results demonstrate that the non-glycosyl-
ated hB7-1 (but not the IgC domain derivative) retains the
ability to bind to CD28 and thereby inhibit T cell prolifera-
tion in vitro.
4. Discussion
Though B7 proteins are known to be highly N-glycosylated,
the relevance of this glycosylation to function has remained an
open question. In the present study, we have used mammalian
and bacterial expression systems in combination to address
this issue. Our principal ¢ndings are: (1) Non-glycosylated
cell surface-associated B7-1, as expressed on tunicamycin-
treated human cell transfectants, retains the capacity to en-
gage the counter-receptor CTLA-4. (2) A soluble derivative of
human B7-1 consisting of the complete extracellular domain
can be produced in bacterial cell transformants and refolded
in functional form. (3) This non-glycosylated, refolded B7-1
produced in bacteria can bind to a soluble derivative of
CTLA-4 in cell-free binding assays and can inhibit costimula-
tion dependent upon B7/CD28 interaction in a cellular pro-
liferation assay. (4) A truncated derivative of B7-1 consisting
of the IgC homologue domain in isolation (free of the amino-
terminal IgV homologue domain, as well as the transmem-
brane and cytoplasmic domains), though readily produced
and e⁄ciently secreted into the bacterial periplasm, cannot
interact with the B7 counter-receptors. Taken together, the
data establish that N-glycosylation is not obligatorily required
for human B7-1 binding to its counter-receptors, and further-
more raise the possibility of using bacterially-produced B7-1
derivatives consisting of the complete B7-1 extracellular do-
main as therapeutic blockers.
Our ¢ndings ¢t well with two other reports that have sim-
ilarly argued, albeit in a more indirect way, against the like-
lihood of an obligatory role for N-glycosylation in B7-1 func-
tion. Based on three-dimensional computer-generated models
of the human B7-1 IgV- and IgC-like domains, Peach et al.
hypothesized that all of the potential N-linked glycosylation
sites in the IgV and IgC domains are positioned in regions
that are essentially opposite the predicted site of counter-re-
ceptor interaction, and are therefore unlikely to modulate the
interaction [25]. Fargeas et al. expressed on L cells a panel of
site-speci¢cally mutated human B7-1 proteins, a subset of
which had one or two N-glycosylation sites removed. One
mutant, M22, yielded a two-fold increase in binding to
CD28 Jurkat cells, and the remaining glycosylation-site mu-
tants exhibited no signi¢cant perturbation in binding [34]. Our
data, based upon use of a glycosylation inhibitor and non-
glycosylated recombinant bacterial derivatives, complements
these observations. Fargeas et al. mutated only a subset of
the N-glycosylation sites within B7-1 and, even for these,
just one or two sites were mutated at a time. Our ¢ndings
demonstrate that N-glycosylation can be fully eliminated with-
out loss of CTLA-4 and CD28 binding, solidifying the con-
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clusion that B7-1 can fold and bind receptor without N-gly-
cosylation.
Though N-glycosylation is apparently not obligatorily re-
quired for counter-receptor interaction, it may nonetheless
play a role in modulating B7 activity and/or in enhancing
the surface expression and solubility of native B7-1 and its
recombinant derivatives. With respect to the latter, it is note-
worthy that whereas B7-1WIg fusion proteins produced in eu-
karyotic cells are very soluble [24^26], a recombinant B7-1
protein encompassing the same complete B7-1 extracellular
domain sequence is insoluble in our hands when expressed
in E. coli. This insolubility may be due to the lack of carbo-
hydrates to stabilize protein conformation. Of note, B7 pro-
teins bear a number of hydrophobic residues on the surfaces
of their extracellular domains which could a¡ect solubility. In
addition, N-glycosylation of native transmembrane B7-1 may
facilitate its export to the cell surface. Our results in fact
indicate that tunicamycin-treated human B7-1-transfected
K562 cells express signi¢cantly lower levels of B7-1 on their
surfaces. The experiments in the present report, however, were
not designed to address these issues, and further analysis will
be required to complete the picture.
The B7-1 extracellular domain consists of one IgV- and one
IgC-homologue domain arrayed in tandem. Despite several
studies, the respective contributions of these Ig superfamily
domains to counter-receptor binding remain unresolved,
with the literature consisting of a mixture of human and mu-
rine B7 analyses and some con£icting ¢ndings. Inobe et al.
showed that an alternatively-spliced form of mouse B7-1 com-
posed of the IgV domain alone binds to both CD28 and
CTLA-4 [35]. This ¢nding is consistent with Fargeas et al.’s
site-speci¢c mutational analysis which identi¢ed critical sites
for counter-receptor binding within the human B7-1 IgV-ho-
mologue domain [34]. In contrast, Guo et al. reported, in
direct con£ict with Inobe et al., that an alternatively-spliced
form of mouse B7-1 consisting of only the IgV-homologue
domain failed to bind to the counter-receptors. These authors
concluded that the IgC-homologue domain, but not the IgV-
homologue domain, of B7-1 constitutes the binding site [36].
By using soluble human B7WIg fusion proteins, Peach et al.
demonstrated that residues of both IgV and IgC domains
are critical for binding [25]. More recently, Ellis et al. dem-
onstrated that the IgV domain of human B7-2 (CD86), but
not that of B7-1 (CD80), is su⁄cient for CTLA-4 binding [26].
In the present report, we have taken a di¡erent experimental
approach to the question, showing for the ¢rst time that an
isolated hB7-1WIgC domain, which can be produced abun-
dantly in soluble form in bacterial periplasm, is incapable of
engaging either of the B7 counter-receptors. Hence, the data
agree with those who argue for either an exclusive role for the
IgV domain or for cooperative interactions between the IgV
and IgC domains. Of note, the IgV domain, unlike the IgC
domain, was not e⁄ciently secreted into bacterial periplasm,
and when refolded under our conditions, did not bind to
counter-receptors (not shown). In this case, however, one can-
not rule out refolding aberrancies.
Gerstmayer et al. recently reported the successful produc-
tion of soluble human B7-1 and B7-2 derivatives in a yeast
expression system [27]. These investigators were apparently
unable to refold functional B7 protein derivatives from bac-
teria, but experimental details were not provided. In contrast,
we have succeeded in e⁄ciently refolding a soluble human B7-
1 derivative, with high yields of the refolded protein (approx-
imately 2 mg/l culture). This represents the ¢rst report of a
soluble recombinant B7 protein derivative produced in bacte-
ria. A key to our B7-1 refolding success may be our applica-
tion of a re¢ned refolding procedure which incorporates the
detergent sodium lauroylsarcosine into the denaturation/rena-
turation bu¡er and omits guanidine or urea denaturants [31].
This procedure, which was applied to single chain Fv refold-
ing in the previous study, may be especially well-suited for the
refolding of IgSF protein derivatives in general and appears to
be e¡ective in settings where guanidine/urea denaturants fail.
Functional recombinant B7-1 derivatives have a variety of
potential experimental and therapeutic applications. On the
experimental side, non-glycosylated bacterial B7-1 derivatives,
when used in combination with cell-free binding assays, pro-
vide a simpli¢ed means for probing structure/function corre-
lations and determinants of counter-receptor a⁄nity. This
type of cell-free analysis avoids confounding factors associ-
ated with the use of whole cells bearing B7 proteins in tradi-
tional binding assays. We have previously shown that another
cell surface molecular interaction of immune relevance,
namely that between CD8 and MHC class I, can be e¡ectively
modeled by using soluble domain derivatives of the respective
proteins [30,37]. On the therapeutic side, recombinant B7 pro-
tein derivatives might be used as competitive blockers of B7-
driven, CD28-mediated costimulation. These would provide
alternatives to CTLA-4WIg which could, by contrast with
CTLA-4WIg, be produced by more economical bacterial (vs.
mammalian) expression systems. Numerous protein engineer-
ing options for recombinant B7-1 derivatives can now be con-
sidered and experimentally evaluated.
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